The strategies involved in the development of therapeutics for neurodegenerative disorders
are very complex and challenging due to the existence of the blood-brain barrier (BBB), a …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

Abstract Alzheimer's disease (AD), the most common neurodegenerative disorder, is
characterized by memory loss and cognitive dysfunction. The accumulation of misfolded …

Oligodendrocyte progenitor cells (OPCs) play pivotal roles in myelin formation and
phagocytosis, communicating with neighboring cells and contributing to the integrity of the …

Drug repositioning and repurposing can enhance traditional drug development efforts and
could accelerate the identification of new treatments for individuals with Alzheimer disease …

The abnormal amyloid‐β accumulation is essential and obbligato in Alzheimer's disease
pathogenesis and natural polyphenols exhibit great potential as amyloid aggregation …

Background Alzheimer's disease (AD) is a devastating neurodegenerative disease leading
to dementia. The field has made significant progress over the last 15 years. AD diagnosis …

Current therapeutic strategies for Alzheimer's disease (AD) treatments mainly focus on β‐
amyloid (Aβ) targeting. However, such therapeutic strategies have limited clinical outcomes …

Alzheimer's disease (AD) is one of the major reasons for 60-80% cases of senile dementia
occurring as a result of the accumulation of plaques and tangles in the hippocampal and …

Investigations of Alzheimer's disease (AD), traumatic brain injury (TBI), and related brain
disorders have provided extensive evidence for involvement of cathepsin B, a lysosomal …